Digimarc Licenses Catalent Pharma Solutions to Deliver Media Enhanced Packaging(TM) Solutions Worldwide

Digimarc Licenses Catalent Pharma Solutions to Deliver Media Enhanced Packaging(TM) Solutions Worldwide
Digimarc Software Will Enable Rich Media Experiences from Product Packaging Using Today's Smart Phones
 

BEAVERTON, Ore., Sep 27, 2010 (BUSINESS WIRE) -- Digimarc Corporation /quotes/comstock/15*!dmrc/quotes/nls/dmrc (DMRC 23.73, +0.73, +3.17%) has licensed its mobile visual search software to New Jersey-based Catalent Pharma Solutions, a leading provider of innovative packaging solutions to the pharmaceutical, biotechnology, and consumer healthcare industries. The agreement allows Catalent to deliver new Media Enhanced Packing solutions to its clients worldwide that will instantly connect consumers to a range of network services from printed packaging, inserts, and labels using smart phones and other digital devices.

"We are very excited to be working with Digimarc to provide our clients with Media Enhanced Packaging solutions that will deliver added value to the consumer while differentiating our customers' products on crowded store shelves," stated Victor Dixon, VP and General Manager, Catalent Pharma Solutions. "We believe that working with Digimarc will uniquely position us to assist the pharmaceutical and consumer packaging industries to better inform and engage the consumers of their products."

Digimarc's mobile software enables the phone's camera to "see" digital data that has been embedded into all forms of printed materials, including advertisements, editorial content, brochures, posters, product packaging, labels and more. Unlike 2D barcodes or QR codes, the digital codes do not take up precious space on packages, and they are imperceptible to human senses, but can easily be detected by computers, networks, and today's most popular smart phones.

"We are pleased to partner with Catalent Pharma Solutions to bring Digimarc's visual search innovations to the packaging industry," said Jeri Owen, Vice President, Marketing, Digimarc. "Together we will address the growing need for brands to build consumer preference and loyalty by delivering innovative new packaging solutions that simplify and enrich the lives of customers using the device they carry with them 24/7."

Catalent is marketing its solution to large, global pharmaceutical companies, mid-sized biotech and generic drug makers, and to small companies in the healthcare and other packaged good markets. The company expects its Media Enhanced Packaging solution to be put into commercial use within the next few months.

About Digimarc

Digimarc Corporation, based in Beaverton, Oregon, is a leading innovator and provider of enabling technologies that create digital identities for all forms of media and many everyday objects. The embedded digital IDs are imperceptible to humans, but not to computers, networks and devices like mobile phones, which can now use cameras and microphones as sensory inputs to "see, hear and understand" the world around them within the context of their environment. Digimarc has built an extensive intellectual property portfolio with patents in digital watermarking, content identification and management, media and object discovery to enable ubiquitous computing, and related technologies. Digimarc develops solutions, licenses its intellectual property, and provides development services to business partners across a range of industries. For more information, please visit www.digimarc.com.

About Catalent

Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,100 at 30 facilities worldwide and in fiscal 2009 generated more than $1.6 billion in annual revenue. For more information, visit www.catalent.com.

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.